Why is Hester Biosciences Ltd falling/rising?

Recent Price Movement and Market Comparison

Hester Biosciences has experienced a sustained downward trajectory over multiple time frames. In the past week, the stock fell by 8.27%, significantly underperforming the Sensex’s modest decline of 2.43%. Over the last month, the stock’s loss widened to 13.59%, compared to the Sensex’s 4.66% drop. Year-to-date, the stock has declined by 13.31%, while the benchmark index has only fallen 4.32%. The longer-term picture is even more concerning, with a one-year return of -36.43% against the Sensex’s positive 6.56% gain. Over three and five years, the stock has lagged the market by substantial margins, posting negative returns of 23.04% and 16.71% respectively, while the Sensex surged 33.80% and 66.82% in the same periods.

Technical Indicators and Trading Activity

On the day of the latest price update, Hester Biosciences underperformed its sector by 2.55%, hitting an intraday low of ₹1,378.80, down 3.71%. The weighted average price indicates that a larger volume of shares traded near the day’s low, signalling selling pressure. The stock is trading below all key moving averages—5-day, 20-day, 50-day, 100-day, and 200-day—highlighting a bearish technical outlook. Notably, investor participation has increased, with delivery volumes on 22 Jan rising by 66.13% compared to the five-day average, suggesting heightened activity but predominantly on the sell side. Despite this, liquidity remains adequate for moderate trade sizes, supporting continued market interest.

Fundamental Analysis: Strengths and Weaknesses

Despite the negative price action, Hester Biosciences exhibits some positive financial metrics. The company reported its highest annual operating cash flow at ₹64.51 crores and a half-yearly return on capital employed (ROCE) of 10.91%, which is relatively strong. Additionally, the debt-to-equity ratio stands at a low 0.63 times, indicating a conservative capital structure. However, these positives are overshadowed by deeper fundamental concerns.

The company’s long-term operating profit growth has been weak, with a compound annual growth rate (CAGR) of -0.36% over the past five years. This stagnation in profitability undermines investor confidence. Furthermore, the firm’s ability to service debt is limited, as evidenced by a high debt-to-EBITDA ratio of 3.73 times. The average ROCE of 9.10% suggests low profitability relative to the total capital employed, which includes both equity and debt. Valuation metrics also raise caution; with a ROCE of 7.7 and an enterprise value to capital employed ratio of 2.5, the stock appears expensive despite trading at a discount compared to peer historical averages.

Investor Sentiment and Market Positioning

Investor sentiment towards Hester Biosciences is tepid. Domestic mutual funds hold virtually no stake in the company, which may reflect concerns about the business model or valuation at current prices. This lack of institutional backing can limit upward momentum. The stock’s poor performance relative to the BSE500 index over one year, three years, and three months further highlights its below-par standing in the market. Interestingly, while the stock price has declined sharply by 36.43% over the past year, the company’s profits have risen by 86.8%, resulting in a low price-to-earnings-growth (PEG) ratio of 0.3. This disparity suggests that the market has yet to fully price in the profit growth, but persistent fundamental weaknesses and valuation concerns continue to weigh heavily on the stock.

Conclusion: Why the Stock is Falling

In summary, Hester Biosciences Ltd’s share price decline on 23-Jan is the result of a combination of weak long-term growth in operating profits, limited debt servicing capacity, and low profitability relative to capital employed. The stock’s consistent underperformance against the Sensex and sector peers over multiple time horizons has eroded investor confidence. Technical indicators reinforce the bearish sentiment, with the stock trading below all major moving averages and increased selling volume near intraday lows. Although the company shows some operational strengths, such as improved cash flow and profit growth, these have not translated into positive market performance due to valuation concerns and lack of institutional support. Investors may remain cautious until the company demonstrates sustained improvement in fundamentals and market positioning.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →